RxDoctor Payments Data

Chun Ho Ng, MD

Family Medicine · Wilson, NCNPI 1649363912

Payments from drug & device makers

$406in general payments, 2019–2025

Across 13 payments — averaging $31.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$125
  • Johnson & Johnson$100
  • AstraZeneca$59
  • Viiv Healthcare Company$39
  • Merck$27
  • Exact Sciences$19
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$38795%
  • Education$185%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$406 in reported general payments places this provider in the 55th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$556
Medicare patients
42
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin488$761,510
OzempicSemaglutide131$174,392
TrulicityDulaglutide96$153,425
JanuviaSitagliptin Phosphate100$152,529
EliquisApixaban87$99,403
MounjaroTirzepatide62$74,658
LinzessLinaclotide58$67,226
JanumetSitagliptin Phos/Metformin Hcl27$41,484
SymbicortBudesonide/Formoterol Fumarate36$17,751
TradjentaLinagliptin12$17,589
Tresiba Flextouch U-100Insulin Degludec16$15,509
Lantus SolostarInsulin Glargine,hum.Rec.Anlog69$14,793
Incruse ElliptaUmeclidinium Bromide18$14,216
Atenolol-ChlorthalidoneAtenolol/Chlorthalidone372$13,679
Varenicline Tartrate21$11,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$27$194,013127 claims
PfizerEliquis$17$99,40387 claims
AstraZenecaSymbicort$59$17,75136 claims
Johnson & JohnsonXarelto$100$11,57811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Wilson

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →